Roche

October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
June 4, 2018

The Future of BioManufacturing: In Silico Modelling

January 11, 2017
Illumina’s NovaSeq Platform Aims for the $100 Human Genome, but is it Good Business?

Illumina’s NovaSeq Platform Targets the $100 Human Genome, but do they Risk Self-Cannibalisation?

Illumina utilised their showcase at the JP Morgan Conference to announce its new DNA sequencers, the NovaSeq 5000 and NovaSeq 6000, promising that by the end of the […]
February 21, 2016
Evolution Infographic: The Rise & Diversification of Biologics

Evolution Infographic: The Rise & Diversification of Biologics

For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that […]
September 17, 2015
Thermo Fisher and Illumina Prepare for Round Two of the Next-Gen Sequencing Battle

Thermo Fisher and Illumina Prepare for Round Two of the Next-Gen Sequencing Battle

Earlier this month Thermo Fisher Scientific announced the launch of two novel next-generation sequencing (NGS) instruments, the Ion S5 and the Ion S5 XL benchtop systems, […]
June 25, 2015
Genentech and Regeneron win Thomson Reuters Allicense Awards for Top BioPharma Deals of the Year

Genentech and Regeneron win Thomson Reuters Allicense Awards for Top BioPharma Deals of the Year

The Intellectual Property and Science business of Thomson Reuters recently honoured Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for […]
October 30, 2014

Roche Post Q3 2014 Results

Roche delivers solid sales growth for the first nine months of 2014 Group sales up 5% at CER1, stable in Swiss francs 4% higher sales in […]
Contact Us